Adenocarcinoma of the lung

Spencer's Pathology of the Lung, Sixth Edition

Volumn 2, Issue , 2012, Pages 1043-1092

  Flieder, Douglas B ^a   Borczuk, Alain C ^b   Noguchi, Masayuki ^c  

^a FOX CHASE CANCER CENTER   (United States)

^b Department of Medicine   (United States)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84955214836     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9781139018760.030     Document Type: Chapter

References (409)

1. Curado MP, Edwards B, Shin HR, et al. Cancer Incidence in Five Continents, vol. IX. Lyon: IARC Scientific Publications, 2007.
2. Kreyberg L, Liebow AA, Uehlinger EA. Histological Typing of Lung Tumours, 1st ed. Geneva: World Health Organization, 1967.
3. Histological Typing of Lung Tumours, 2nd ed. Geneva: World Health Organization, 1981.
4. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological Typing of Lung and Pleural Tumours, 3rd ed. Berlin: Springer-Verlag, 1999.
5. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004.
6. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-85.
7. Borczuk AC, Qian F, Kazeros A, et al. Invasive size is an independent predictor of survival in pulmonary adenocarcinoma. Am J Surg Pathol 2009; 33: 462-9.
8. Clayton F. Bronchioloalveolar carcinomas. Cell types, patterns of growth, and prognostic correlates. Cancer 1986; 57: 1555-64.
9. Daly RC, Trastek VF, Pairolero PC, et al. Bronchoalveolar carcinoma: factors affecting survival. Ann Thorac Surg 1991; 51: 368-76; discussion 376-7.
10. Goldstein NS, Mani A, Chmielewski G, Welsh R, Pursel S. Prognostic factors in T1 NO MO adenocarcinomas and bronchioloalveolar carcinomas of the lung. Am J Clin Pathol 1999; 112: 391-402.
11. Manning JT Jr, Spjut HJ, Tschen JA. Bronchioloalveolar carcinoma: The significance of two histopathologic types. Cancer 1984; 54: 525-34.
12. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995; 75: 2844-52.
13. Riquet M, Foucault C, Berna P, et al. Prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping. Ann Thorac Surg 2006; 81: 1988-95.
14. Yim J, Zhu LC, Chiriboga L, et al. Histologic features are important prognostic indicators in early stages lung adenocarcinomas. Mod Pathol 2007; 20: 233-41.
15. Auerbach O. Pathogenesis of lung cancer. Compr Ther 1981; 7: 11-21.
16. Dermer GB. Autoradiography of cellular glycoproteins reveals histogenesis of bronchogenic adenocarcinomas. Cancer 1981; 47: 2000-6.
17. Dermer GB. Origin of bronchioloalveolar carcinoma and peripheral bronchial adenocarcinoma. Cancer 1982; 49: 881-7.
18. Takeuchi T, Tomida S, Yatabe Y, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 2006; 24: 1679-88.
19. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007; 450: 893-8.
20. Testa JR, Liu Z, Feder M, et al. Advances in the analysis of chromosome alterations in human lung carcinomas. Cancer Genet Cytogenet 1997; 95: 20-32.
21. Balsara BR, Testa JR. Chromosomal imbalances in human lung cancer. Oncogene 2002; 21: 6877-83.
22. Choi JS, Zheng LT, Ha E, et al. Comparative genomic hybridization array analysis and real-time PCR reveals genomic copy number alteration for lung adenocarcinomas. Lung 2006; 184: 355-62.
23. Kang JU, Koo SH, Kwon KC, Park JW, Kim JM. Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. Cancer Genet Cytogenet 2008; 182: 1-11.
24. Mertens F, Johansson B, Hoglund M, Mitelman F. Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res 1997; 57: 2765-80.
25. Wong MP, Fung LF, Wang E, et al. Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers. Cancer 2003; 97: 1263-70.
26. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001; 98: 13790-5.
27. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 2001; 98: 13784-9.
28. Hayes DN, Monti S, Parmigiani G, et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 2006; 24: 5079-90.
29. Tomida S, Koshikawa K, Yatabe Y, et al. Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene 2004; 23: 5360-70.
30. Virtanen C, Ishikawa Y, Honjoh D, et al. Integrated classification of lung tumors and cell lines by expression profiling. Proc Natl Acad Sci USA 2002; 99: 12357-62.
31. Tomida S, Yatabe Y, Yanagisawa K, Mitsudomi T, Takahashi T. Throwing new light on lung cancer pathogenesis: updates on three recent topics. Cancer Sci 2005; 96: 63-8.
32. Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 2005; 29: 633-9.
33. Cagle PT, Allen TC, Dacic S, et al. Revolution in lung cancer: new challenges for the surgical pathologist. Arch Pathol Lab Med 2011; 135: 110-6.
34. Choi JH, Chung HC, Yoo NC, et al. Changing trends in histologic types of lung cancer during the last decade (1981-1990) in Korea: a hospital-based study. Lung Cancer 1994; 10: 287-96.
35. Limsila T, Mitacek EJ, Caplan LS, Brunnemann KD. Histology and smoking history of lung cancer cases and implications for prevention in Thailand. Prev Med 1994; 23: 249-52.
36. Muscat JE, Wynder EL. Lung cancer pathology in smokers, ex-smokers and never smokers. Cancer Lett 1995; 88: 1-5.
37. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995; 75: 191-202.
38. Tse LA, Mang OW, Yu IT, et al. Cigarette smoking and changing trends of lung cancer incidence by histological subtype among Chinese male population. Lung Cancer 2009; 66: 22-7.
39. Thun MJ, Lally CA, Flannery JT, et al. Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst 1997; 89: 1580-6.
40. Egleston BL, Meireles SI, Flieder DB, Clapper ML. Population-based trends in lung cancer incidence in women. Semin Oncol 2009; 36: 506-15.
41. Ernster VL. The epidemiology of lung cancer in women. Ann Epidemiol 1994; 4: 102-10.
42. Gabrielson E. Worldwide trends in lung cancer pathology. Respirology 2006; 11: 533-8.
43. Levi F, Franceschi S, La Vecchia C, Randimbison L, Te VC. Lung carcinoma trends by histologic type in Vaud and Neuchatel, Switzerland, 1974-1994. Cancer 1997; 79: 906-14.
44. Shields PG. Molecular epidemiology of smoking and lung cancer. Oncogene 2002; 21: 6870-6.
45. Stratton K, Shetty P, Wallace R, Bondurant S. Clearing the smoke: the science base for tobacco harm reduction - executive summary. Tob Control 2001; 10: 189-95.
46. Jedrychowski W, Becher H, Wahrendorf J, Basa-Cierpialek Z, Gomola K. Effect of tobacco smoking on various histological types of lung cancer. J Cancer Res Clin Oncol 1992; 118: 276-82.
47. Lubin JH, Blot WJ. Assessment of lung cancer risk factors by histologic category. J Natl Cancer Inst 1984; 73: 383-9.
48. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
49. Vastag B. Attention turns to lung cancer in nonsmokers. J Natl Cancer Inst 2006; 98: 664-5.
50. Wakelee HA, Chang ET, Gomez SL, et al. Lung cancer incidence in never smokers. J Clin Oncol 2007; 25: 472-8.
51. Freedman ND, Leitzmann MF, Hollenbeck ch, Schatzkin A, Abnet CC. Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol 2008; 9: 649-56.
52. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers - a different disease. Nat Rev Cancer 2007; 7: 778-90.
53. Fanucchi O, Ambrogi MC, Dini P, et al. Surgical treatment of non-small cell lung cancer in octogenarians. Interact Cardiovasc Thorac Surg 2011; 12: 749-53.
54. Port JL, Kent M, Korst RJ, et al. Surgical resection for lung cancer in the octogenarian. Chest 2004; 126: 733-8.
55. McDuffie HH, Klaassen DJ, Dosman JA. Characteristics of patients with primary lung cancer diagnosed at age of 50 years or younger. Chest 1989; 96: 1298-301.
56. Mizushima Y, Yokoyama A, Ito M, et al. Lung carcinoma in patients age younger than 30 years. Cancer 1999; 85: 1730-3.
57. Ramalingam S, Pawlish K, Gadgeel S, Demers R, Kalemkerian GP. Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database. J Clin Oncol 1998; 16: 651-7.
58. Tian DL, Liu HX, Zhang L, et al. Surgery for young patients with lung cancer. Lung Cancer 2003; 42: 215-20.
59. Whooley BP, Urschel JD, Antkowiak JG, Takita H. Bronchogenic carcinoma in patients age 30 and younger. Ann Thorac Cardiovasc Surg 2000; 6: 86-8.
60. Benjamin DR, Cahill JL. Bronchioloalveolar carcinoma of the lung and congenital cystic adenomatoid malformation. Am J Clin Pathol 1991; 95: 889-92.
61. Granata C, Gambini C, Balducci T, et al. Bronchioloalveolar carcinoma arising in congenital cystic adenomatoid malformation in a child: a case report and review on malignancies originating in congenital cystic adenomatoid malformation. Pediatr Pulmonol 1998; 25: 62-6.
62. Kaslovsky RA, Purdy S, Dangman BC, et al. Bronchioloalveolar carcinoma in a child with congenital cystic adenomatoid malformation. Chest 1997; 112: 548-51.
63. Lantuejoul S, Ferretti GR, Goldstraw P, et al. Metastases from bronchioloalveolar carcinomas associated with long-standing type 1 congenital cystic adenomatoid malformations. A report of two cases. Histopathology 2006; 48: 204-6.
64. Lantuejoul S, Nicholson AG, Sartori G, et al. Mucinous cells in type 1 pulmonary congenital cystic adenomatoid malformation as mucinous bronchioloalveolar carcinoma precursors. Am J Surg Pathol 2007; 31: 961-9.
65. MacSweeney F, Papagiannopoulos K, Goldstraw P, et al. An assessment of the expanded classification of congenital cystic adenomatoid malformations and their relationship to malignant transformation. Am J Surg Pathol 2003; 27: 1139-46.
66. Papagiannopoulos K, Hughes S, Nicholson AG, Goldstraw P. Cystic lung lesions in the pediatric and adult population: surgical experience at the Brompton Hospital. Ann Thorac Surg 2002; 73: 1594-8.
67. West D, Nicholson AG, Colquhoun I, Pollock J. Bronchioloalveolar carcinoma in congenital cystic adenomatoid malformation of lung. Ann Thorac Surg 2007; 83: 687-9.
68. Kayton ML, He M, Zakowski MF, et al. Primary lung adenocarcinomas in children and adolescents treated for pediatric malignancies. J Thorac Oncol 2010; 5: 1764-71.
69. Travis WD, Linnoila RI, Horowitz M, et al. Pulmonary nodules resembling bronchioloalveolar carcinoma in adolescent cancer patients. Mod Pathol 1988; 1: 372-7.
70. Beckles MA, Spiro SG, Colice GL, Rudd RM. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes. Chest 2003; 123: 97S-104S.
71. Patel AM, Peters SG. Clinical manifestations of lung cancer. Mayo Clin Proc 1993; 68: 273-7.
72. Bennani-Baiti N, Davis MP. Cytokines and cancer anorexia cachexia syndrome. Am J Hosp Palliat Care 2008; 25: 407-11.
73. Fortunati N, Manti R, Birocco N, et al. Pro-inflammatory cytokines and oxidative stress/antioxidant parameters characterize the bio-humoral profile of early cachexia in lung cancer patients. Oncol Rep 2007; 18: 1521-7.
74. Laviano A, Meguid MM, Inui A, Muscaritoli M, Rossi-Fanelli F. Therapy insight: cancer anorexia-cachexia syndrome - when all you can eat is yourself. Nat Clin Pract Oncol 2005; 2: 158-65.
75. Plata-Salaman CR. Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. Nutrition 2000; 16: 1009-12.
76. Chute CG, Greenberg ER, Baron J, et al. Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. Cancer 1985; 56: 2107-11.
77. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Lung carcinoma symptoms - an independent predictor of survival and an important mediator of African-American disparity in survival. Cancer 2004; 101: 1655-63.
78. Lisa JR, Trinidad S, Rosenblatt MB. Site of origin, histogenesis, and cytostructure of bronchogenic carcinoma. Am J Clin Pathol 1965; 44: 375-84.
79. Anderson TM, Moy PM, Holmes EC. Factors affecting survival in superior sulcus tumors. J Clin Oncol 1986; 4: 1598-603.
80. Quinn D, Gianlupi A, Broste S. The changing radiographic presentation of bronchogenic carcinoma with reference to cell types. Chest 1996; 110: 1474-9.
81. Shahian DM, Neptune WB, Ellis FH Jr. Pancoast tumors: improved survival with preoperative and postoperative radiotherapy. Ann Thorac Surg 1987; 43: 32-8.
82. Stanford W, Barnes RP, Tucker ch. Influence of staging in superior sulcus (Pancoast) tumors of the lung. Ann Thorac Surg 1980; 29: 406-9.
83. Lehar TJ, Carr DT, Miller WE, Payne WS, Woolner LB. Roentgenographic appearance of bronchogenic adenocarcinoma. Am Rev Respir Dis 1967; 96: 245-8.
84. Woodring JH, Stelling CB. Adenocarcinoma of the lung: a tumor with a changing pleomorphic character. AJR Am J Roentgenol 1983; 140: 657-64.
85. Byrd RB, Carr DT, Miller WE, Payne WS, Woolner LB. Radiographic abnormalities in carcinoma of the lung as related to histological cell type. Thorax 1969; 24: 573-5.
86. Garland LH. The rate of growth and natural duration of primary bronchial cancer. Am J Roentgenol Radium Ther Nucl Med 1966; 96: 604-11.
87. Schraufnagel D, Peloquin A, Pare JA, Wang NS. Differentiating bronchioloalveolar carcinoma from adenocarcinoma. Am Rev Respir Dis 1982; 125: 74-9.
88. Schraufnagel DE, Peloquin A, Pare JA, Wang NS. Radiographic differences between two subtypes of bronchioloalveolar carcinoma. J Can Assoc Radiol 1985; 36: 244-7.
89. Siegelman SS, Khouri NF, Leo FP, et al. Solitary pulmonary nodules: CT assessment. Radiology 1986; 160: 307-12.
90. Zerhouni EA, Stitik FP, Siegelman SS, et al. CT of the pulmonary nodule: a cooperative study. Radiology 1986; 160: 319-27.
91. Zwirewich CV, Vedal S, Miller RR, Müller NL. Solitary pulmonary nodule: high-resolution CT and radiologicpathologic correlation. Radiology 1991; 179: 469-76.
92. Hill CA. "Tail" signs associated with pulmonary lesions: critical reappraisal. AJR Am J Roentgenol 1982; 139: 311-6.
93. Webb WR. The pleural tail sign. Radiology 1978; 127: 309-13.
94. Cohen S, Hossain SA. Primary carcinoma of the lung. A review of 417 histologically proved cases. Dis Chest 1966; 49: 67-74.
95. Kundel HL. Predictive value and threshold detectability of lung tumors. Radiology 1981; 139: 25-9.
96. Godoy MC, Naidich DP. Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: recommended interim guidelines for assessment and management. Radiology 2009; 253: 606-22.
97. Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008; 246: 697-722.
98. Lee HY, Goo JM, Lee HJ, et al. Usefulness of concurrent reading using thin-section and thick-section CT images in subcentimetre solitary pulmonary nodules. Clin Radiol 2009; 64: 127-32.
99. Aoki T, Tomoda Y, Watanabe H, et al. Peripheral lung adenocarcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival. Radiology 2001; 220: 803-9.
100. Choi JA, Kim JH, Hong KT, Kim HS, Oh YW, Kang EY. et al. CT bronchus sign in malignant solitary pulmonary lesions: value in the prediction of cell type. Eur Radiol 2000; 10: 1304-9.
101. Ishikawa H, Koizumi N, Morita T, et al. Ultrasmall pulmonary opacities on multidetector-row high-resolution computed tomography: a prospective radiologic-pathologic examination. J Comput Assist Tomogr 2005; 29: 621-5.
102. Kim HY, Shim YM, Lee KS, et al. Persistent pulmonary nodular groundglass opacity at thin-section CT: histopathologic comparisons. Radiology 2007; 245: 267-75.
103. Kim TJ, Goo JM, Lee KW, Park CM, Lee HJ. Clinical, pathological and thinsection CT features of persistent multiple ground-glass opacity nodules: comparison with solitary ground-glass opacity nodule. Lung Cancer 2009; 64: 171-8.
104. Kishi K, Homma S, Kurosaki A, et al. Small lung tumors with the size of 1cm or less in diameter: clinical, radiological, and histopathological characteristics. Lung Cancer 2004; 44: 43-51.
105. Nakazono T, Sakao Y, Yamaguchi K, et al. Subtypes of peripheral adenocarcinoma of the lung: differentiation by thin-section CT. Eur Radiol 2005; 15: 1563-8.
106. Suzuki K, Asamura H, Kusumoto M, Kondo H, Tsuchiya R. "Early" peripheral lung cancer: prognostic significance of ground glass opacity on thin-section computed tomographic scan. Ann Thorac Surg 2002; 74: 1635-9.
107. Takashima S, Maruyama Y, Hasegawa M, et al. CT findings and progression of small peripheral lung neoplasms having a replacement growth pattern. AJR Am J Roentgenol 2003; 180: 817-26.
108. Takashima S, Sone S, Li F, et al. Small solitary pulmonary nodules (< or 1/41 cm) detected at population-based CT screening for lung cancer: Reliable high-resolution CT features of benign lesions. AJR Am J Roentgenol 2003; 180: 955-64.
109. Travis WD, Garg K, Franklin WA, et al. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol 2005; 23: 3279-87.
110. Kodama K, Higashiyama M, Yokouchi H, et al. Natural history of pure ground-glass opacity after longterm follow-up of more than 2 years. Ann Thorac Surg 2002; 73: 386-92; discussion 92-3.
111. Hiramatsu M, Inagaki T, Inagaki T, et al. Pulmonary ground-glass opacity (GGO) lesions-large size and a history of lung cancer are risk factors for growth. J Thorac Oncol 2008; 3: 1245-50.
112. Saito H, Yamada K, Hamanaka N, et al. Initial findings and progression of lung adenocarcinoma on serial computed tomography scans. J Comput Assist Tomogr 2009; 33: 42-8.
113. Takashima S, Maruyama Y, Hasegawa M, et al. Prognostic significance of high-resolution CT findings in small peripheral adenocarcinoma of the lung: a retrospective study on 64 patients. Lung Cancer 2002; 36: 289-95.
114. Yang ZG, Sone S, Takashima S, et al. High-resolution CT analysis of small peripheral lung adenocarcinomas revealed on screening helical CT. AJR Am J Roentgenol 2001; 176: 1399-407.
115. Diederich S. Pulmonary nodules: do we need a separate algorithm for non-solid lesions? Cancer Imaging 2009; 9 Spec No A: S126-8.
116. MacMahon H. Compliance with Fleischner Society guidelines for management of lung nodules: lessons and opportunities. Radiology 2010; 255: 14-5.
117. MacMahon H, Austin JH, Gamsu G, et al. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 2005; 237: 395-400.
118. Tateishi U, Uno H, Yonemori K, et al. Prediction of lung adenocarcinoma without vessel invasion: a CT scan volumetric analysis. Chest 2005; 128: 3276-83.
119. Yoshino I, Nakanishi R, Kodate M, et al. Pleural retraction and intratumoral air-bronchogram as prognostic factors for stage I pulmonary adenocarcinoma following complete resection. Int Surg 2000; 85: 105-12.
120. Hashizume T, Yamada K, Okamoto N, et al. Prognostic significance of thinsection CT scan findings in small-sized lung adenocarcinoma. Chest 2008; 133: 441-7.
121. Matsuguma H, Yokoi K, Anraku M, et al. Proportion of ground-glass opacity on high-resolution computed tomography in clinical T1 N0 M0 adenocarcinoma of the lung: a predictor of lymph node metastasis. J Thorac Cardiovasc Surg 2002; 124: 278-84.
122. Okada M, Nishio W, Sakamoto T, et al. Correlation between computed tomographic findings, bronchioloalveolar carcinoma component, and biologic behavior of small-sized lung adenocarcinomas. J Thorac Cardiovasc Surg 2004; 127: 857-61.
123. Glynn C, Zakowski MF, Ginsberg MS. Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features? J Thorac Oncol 2010; 5: 344-8.
124. Berghmans T, Dusart M, Paesmans M, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in nonsmall cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008; 3: 6-12.
125. Mak RH, Digumarthy SR, Muzikansky A, et al. Role of 18Ffluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncologist 2011; 16: 319-26.
126. Pastorino U, Landoni C, Marchiano A, et al. Fluorodeoxyglucose uptake measured by positron emission tomography and standardized uptake value predicts long-term survival of CT screening detected lung cancer in heavy smokers. J Thorac Oncol 2009; 4: 1352-6.
127. Sun JS, Park KJ, Sheen SS, et al. Clinical usefulness of the fluorodeoxyglucose (FDG)-PET maximal standardized uptake value (SUV) in combination with CT features for the differentiation of adenocarcinoma with a bronchioloalveolar carcinoma from other subtypes of non-small cell lung cancers. Lung Cancer 2009; 66: 205-10.
128. Um SW, Kim H, Koh WJ, et al. Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I nonsmall cell lung cancer. J Thorac Oncol 2009; 4: 1331-6.
129. Heyneman LE, Patz EF. PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer 2002; 38: 261-6.
130. Lee HY, Lee KS, Han J, et al. Mucinous versus nonmucinous solitary pulmonary nodular bronchioloalveolar carcinoma: CT and FDG PET findings and pathologic comparisons. Lung Cancer 2009; 65: 170-5.
131. Nakamura H, Hirata T, Kitamura H, Nishikawa J. Correlation of the standardized uptake value in FDG-PET with the expression level of cell-cyclerelated molecular biomarkers in resected non-small cell lung cancers. Ann Thorac Cardiovasc Surg 2009; 15: 304-10.
132. Watanabe K, Nomori H, Ohtsuka T, et al. [F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas. Jpn J Clin Oncol 2006; 36: 403-9.
133. Edwards CW. Pulmonary adenocarcinoma: review of 106 cases and proposed new classification. J Clin Pathol 1987; 40: 125-35.
134. Hirata H, Noguchi M, Shimosato Y, Uei Y, Goya T. Clinicopathologic and immunohistochemical characteristics of bronchial gland cell type adenocarcinoma of the lung. Am J Clin Pathol 1990; 93: 20-5.
135. Hishida T, Ishii G, Kodama T, et al. Centrally located adenocarcinoma with endobronchial polypoid growth: clinicopathological analysis of five cases. Pathol Int 2011; 61: 73-9.
136. Iyoda A, Hiroshima K, Toyozaki T, et al. Clear cell adenocarcinoma with endobronchial polypoid growth. Pathol Int 2000; 50: 979-83.
137. Kodama T, Shimosato Y, Koide T, Watanabe S, Yoneyama T. Endobronchial polypoid adenocarcinoma of the lung. Histological and ultrastructural studies of five cases. Am J Surg Pathol 1984; 8: 845-54.
138. Flieder DB, Vazquez M, Carter D, et al. Pathologic findings of lung tumors diagnosed on baseline CT screening. Am J Surg Pathol 2006; 30: 606-13.
139. Zell JA, Ou SH, Ziogas A, Anton-Culver H. Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol 2005; 23: 8396-405.
140. Aida S, Shimazaki H, Sato K, et al. Prognostic significance of frequent acidophilic nuclear inclusions in adenocarcinoma of the lung with immunohistochemical and ultrastructural studies. Cancer 2001; 91: 1896-904.
141. Mizutani Y, Nakajima T, Morinaga S, et al. Immunohistochemical localization of pulmonary surfactant apoproteins in various lung tumors. Special reference to nonmucus producing lung adenocarcinomas. Cancer 1988; 61: 532-7.
142. Axiotis CA, Jennings TA. Observations on bronchiolo-alveolar carcinomas with special emphasis on localized lesions. A clinicopathological, ultrastructural, and immunohistochemical study of 11 cases. Am J Surg Pathol 1988; 12: 918-31.
143. Terasaki H, Niki T, Matsuno Y, et al. Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol 2003; 27: 937-51.
144. Dacic S, Shuai Y, Yousem S, Ohori P, Nikiforova M. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol 2010; 23: 159-68.
145. De Oliveira Duarte Achcar R, Nikiforova MN, Yousem SA. Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile. Am J Clin Pathol 2009; 131: 694-700.
146. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-75.
147. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008; 32: 810-27.
148. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 2010; 34: 1155-62.
149. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011; 24: 653-64.
150. Solis LM, Raso MG, Kalhor N, et al. Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases. Am J Clin Pathol 2010; 133: 133-40.
151. Nakamura S, Koshikawa T, Sato T, Hayashi K, Suchi T. Extremely well differentiated papillary adenocarcinoma of the lung with prominent cilia formation. Acta Pathol Jpn 1992; 42: 745-50.
152. Usami N, Yoshioka H, Mori S, et al. Primary lung adenocarcinoma with heterotopic bone formation. Jpn J Thorac Cardiovasc Surg 2005; 53: 102-5.
153. Okudela K, Woo T, Mitsui H, et al. Proposal of an improved histological sub-typing system for lung adenocarcinoma - significant prognostic values for stage I disease. Int J Clin Exp Pathol 2010; 3: 348-66.
154. Sorensen JB, Hirsch FR, Olsen J. The prognostic implication of histopathologic subtyping of pulmonary adenocarcinoma according to the classification of the World Health Organization. An analysis of 259 consecutive patients with advanced disease. Cancer 1988; 62: 361-7.
155. Sorensen JB, Olsen JE. Prognostic implications of histopathologic subtyping in patients with surgically treated stage I or II adenocarcinoma of the lung. J Thorac Cardiovasc Surg 1989; 97: 245-51.
156. Moran CA, Jagirdar J, Suster S. Papillary lung carcinoma with prominent "morular" component. Am J Clin Pathol 2004; 122: 106-9.
157. Salisbury JR, Darby AJ, Whimster WF. Papillary adenocarcinoma of lung with psammoma bodies: report of a case derived from type II pneumocytes. Histopathology 1986; 10: 877-84.
158. Amin MB, Tamboli P, Merchant SH, et al. Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance. Am J Surg Pathol 2002; 26: 358-64.
159. Kamiya K, Hayashi Y, Douguchi J, et al. Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma. Mod Pathol 2008; 21: 992-1001.
160. Kuroda N, Hamaguchi N, Takeuchi E, et al. Lung adenocarcinoma with a micropapillary pattern: a clinicopathological study of 25 cases. APMIS 2006; 114: 381-5.
161. Miyoshi T, Satoh Y, Okumura S, et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol 2003; 27: 101-9.
162. Sanchez-Mora N, Presmanes MC, Monroy V, et al. Micropapillary lung adenocarcinoma: a distinctive histologic subtype with prognostic significance. Case series. Hum Pathol 2008; 39: 324-30.
163. Yamaguchi Y, Ishii G, Kojima M, et al. Histopathologic features of the tumor budding in adenocarcinoma of the lung: tumor budding as an index to predict the potential aggressiveness. J Thorac Oncol 2010; 5: 1361-8.
164. Roh MS, Lee JI, Choi PJ, Hong YS. Relationship between micropapillary component and micrometastasis in the regional lymph nodes of patients with stage I lung adenocarcinoma. Histopathology 2004; 45: 580-6.
165. Chung CK, Zaino R, Stryker JA, O’Neill M Jr, DeMuth WE Jr. Carcinoma of the lung: evaluation of histological grade and factors influencing prognosis. Ann Thorac Surg 1982; 33: 599-604.
166. Kobayashi N, Toyooka S, Soh J, et al. Risk factors for recurrence and unfavorable prognosis in patients with stage I non-small cell lung cancer and a tumor diameter of 20 mm or less. J Thorac Oncol 2007; 2: 808-12.
167. Maeshima AM, Tochigi N, Yoshida A, et al. Histological scoring for small lung adenocarcinomas 2 cm or less in diameter: a reliable prognostic indicator. J Thorac Oncol 2010; 5: 333-9.
168. Nakazato Y, Minami Y, Kobayashi H, et al. Nuclear grading of primary pulmonary adenocarcinomas: correlation between nuclear size and prognosis. Cancer 2010; 116: 2011-9.
169. Petersen I, Kotb WF, Friedrich KH, et al. Core classification of lung cancer: correlating nuclear size and mitoses with ploidy and clinicopathological parameters. Lung Cancer 2009; 65: 312-8.
170. Papanicolaou GN. Atlas of Exfoliative Cytology. Cambridge, MA: Harvard University Press. Commonwealth Fund, 1954.
171. Vazquez MF, Koizumi JH, Henschke CI, Yankelevitz DF. Reliability of cytologic diagnosis of early lung cancer. Cancer 2007; 111: 252-8.
172. Gupta RK. Value of sputum cytology in the differential diagnosis of alveolar cell carcinoma from bronchogenic adenocarcinoma. Acta Cytol 1981; 25: 255-8.
173. Raz DJ, Zell JA, Karnezis AN, et al. Misclassification of bronchioloalveolar carcinoma with cytologic diagnosis of lung cancer. J Thorac Oncol 2006; 1: 943-8.
174. Roger V, Nasiell M, Linden M, Enstad I. Cytologic differential diagnosis of bronchiolo-alveolar carcinoma and bronchogenic adenocarcinoma. Acta Cytol 1976; 20: 303-7.
175. Smith JH, Frable WJ. Adenocarcinoma of the lung cytologic correlation with histologic types. Acta Cytol 1974; 18: 316-20.
176. Elson CE, Moore SP, Johnston WW. Morphologic and immunocytochemical studies of bronchioloalveolar carcinoma at Duke University Medical Center, 1968-1986. Anal Quant Cytol Histol 1989; 11: 261-74.
177. Chen KT. Psammoma bodies in fineneedle aspiration cytology of papillary adenocarcinoma of the lung. Diagn Cytopathol 1990; 6: 271-4.
178. Imai T, Suga M, Kaimori M, et al. Peripheral pulmonary papillary adenocarcinoma with prominent cilia: report of a rare case that was difficult to diagnose preoperatively. Acta Cytol 2010; 54: 949-57.
179. Barbazza R, Toniolo L, Pinarello A, et al. Accuracy of bronchial aspiration cytology in typing operable (stage I-II) pulmonary carcinomas. Diagn Cytopathol 1992; 8: 3-7.
180. Foot NC. The identification of types of pulmonary cancer in cytologic smears. Am J Pathol 1952; 28: 963-83.
181. Suprun H, Pedio G, Ruttner JR. The diagnostic reliability of cytologic typing in primary lung cancer with a review of the literature. Acta Cytol 1980; 24: 494-500.
182. Tanaka T, Yamamoto M, Tamura T, et al. Cytologic and histologic correlation in primary lung cancer. A study of 154 cases with resectable tumors. Acta Cytol 1985; 29: 49-56.
183. Yilmaz A, Uskul TB, Bayramgurler B, Baran R. Cell type accuracy of transthoracic fine needle aspiration material in primary lung cancer. Respirology 2001; 6: 91-4.
184. Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011; 6: 451-8.
185. Billah S, Stewart J, Staerkel G, et al. EGFR and KRAS mutations in lung carcinoma: Molecular testing by using cytology specimens. Cancer Cytopathol 2011; 119: 111-7.
186. Boldrini L, Gisfredi S, Ursino S, et al. Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. J Thorac Oncol 2007; 2: 1086-90.
187. Khayyata S, Yun S, Pasha T, et al. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol 2009; 37: 178-83.
188. Nicholson AG, Gonzalez D, Shah P, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 2010; 5: 436-41.
189. Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: A retrospective study of 103 cases with surgical correlation. Cancer 2011; 117: 3416-23.
190. Schuurbiers OC, Looijen-Salamon MG, Ligtenberg MJ, van der Heijden HF. A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates. J Thorac Oncol 2010; 5: 1664-7.
191. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol 2010; 41: 20-5.
192. Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol 2010; 23: 654-61.
193. Bejarano PA, Baughman RP, Biddinger PW, et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Modern Pathol 1996; 9: 445-52.
194. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011; 35: 15-25.
195. Nicholson AG, McCormick CJ, Shimosato Y, Butcher DN, Sheppard MN. The value of PE-10, a monoclonal antibody against pulmonary surfactant, in distinguishing primary and metastatic lung tumours. Histopathology 1995; 27: 57-60.
196. Au NH, Gown AM, Cheang M, et al. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 2004; 12: 240-7.
197. Bakshi N, Kunju LP, Giordano T, Shah RB. Expression of renal cell carcinoma antigen (RCC) in renal epithelial and nonrenal tumors: diagnostic Implications. Appl Immunohistochem Mol Morphol 2007; 15: 310-5.
198. Butnor KJ, Burchette JL, Sporn TA, Hammar SP, Roggli VL. The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using a single-source antibody with a review of the literature. Arch Pathol Lab Med 2004; 128: 538-43.
199. Fan Z, van de Rijn M, Montgomery K, Rouse RV. Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol 2003; 16: 137-44.
200. Striebel JM, Dacic S, Yousem SA. Gross cystic disease fluid protein-(GCDFP-15): expression in primary lung adenocarcinoma. Am J Surg Pathol 2008; 32: 426-32.
201. Tan J, Sidhu G, Greco MA, Ballard H, Wieczorek R. Villin, cytokeratin 7, and cytokeratin 20 expression in pulmonary adenocarcinoma with ultrastructural evidence of microvilli with rootlets. Hum Pathol 1998; 29: 390-6.
202. Wang LJ, Greaves WO, Sabo E, et al. GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors. Appl Immunohistochem Mol Morphol 2009; 17: 505-11.
203. Yatabe Y, Koga T, Mitsudomi T, Takahashi T. CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas. J Pathol 2004; 203: 645-52.
204. Howe MC, Chapman A, Kerr K, et al. Neuroendocrine differentiation in nonsmall cell lung cancer and its relation to prognosis and therapy. Histopathology 2005; 46: 195-201.
205. Ionescu DN, Treaba D, Gilks CB, et al. Nonsmall cell lung carcinoma with neuroendocrine differentiation - an entity of no clinical or prognostic significance. Am J Surg Pathol 2007; 31: 26-32.
206. Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 2010; 5: 442-7.
207. Ring BZ, Seitz RS, Beck RA, et al. A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod Pathol 2009; 22: 1032-43.
208. Rossi G, Pelosi G, Graziano P, Barbareschi M, Papotti M. A reevaluation of the clinical significance of histological subtyping of non - small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol 2009; 17: 206-18.
209. Travis WD, Rekhtman N, Riley GJ, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 2010; 5: 411-4.
210. Yanagita E, Imagawa N, Ohbayashi C, Itoh T. Rapid multiplex immunohistochemistry using the 4-antibody cocktail YANA-4 in differentiating primary adenocarcinoma from squamous cell carcinoma of the lung. Appl Immunohistochem Mol Morphol 2011; 19: 509-13.
211. Terry J, Leung S, Laskin J, et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010; 34: 1805-11.
212. Fatima N, Cohen C, Lawson D, Siddiqui MT. TTF-1 and Napsin A double stain: A useful marker for diagnosing lung adenocarcinoma on fine-needle aspiration cell blocks. Cancer Cytopathol 2011; 119: 127-33. doi: 10.1002/dc.21678.
213. Chu PG, Weiss LM. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Modern Pathol 2002; 15: 6-10.
214. Downey P, Cummins R, Moran M, Gulmann C. If it’s not CK5/6 positive, TTF-1 negative it’s not a squamous cell carcinoma of lung. Apmis 2008; 116: 526-9.
215. Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 2011; 24: 1348-59.
216. Sigel CS, Friedlander MA, Zakowski MF, et al. Subtyping of nonsmall cell lung carcinoma: comparison of cytology and small biopsy specimens. Mod Pathol 2010; 23: 414A.
217. Bedrossian CW, Weilbaecher DG, Bentinck DC, Greenberg SD. Ultrastructure of human bronchioloalveolar cell carcinoma. Cancer 1975; 36: 1399-413.
218. Hammar S. Adenocarcinoma and large cell undifferentiated carcinoma of the lung. Ultrastruct Pathol 1987; 11: 263-91.
219. Hammar S. The use of electron microscopy and immunohistochemistry in the diagnosis and understanding of lung neoplasms. Clin Lab Med 1987; 7: 1-30.
220. Bombi JA, Martinez A, Ramirez J, et al. Ultrastructural and molecular heterogeneity in non-small cell lung carcinomas: study of 110 cases and review of the literature. Ultrastruct Pathol 2002; 26: 211-8.
221. Hammar S, Bockus D, Remington F, Cooper L. The unusual spectrum of neuroendocrine lung neoplasms. Ultrastruct Pathol 1989; 13: 515-60.
222. Sorhaug S, Steinshamn S, Haaverstad R, et al. Expression of neuroendocrine markers in non-small cell lung cancer. APMIS 2007; 115: 152-63.
223. McGregor DH, Dixon AY, McGregor DK. Adenocarcinoma of the lung: a comparative diagnostic study using light and electron microscopy. Hum Pathol 1988; 19: 910-3.
224. Sidhu GS, Forrester EM. Glycogen-rich Clara cell-type bronchiolo-alveolar carcinoma: light and electron microscopic study. Cancer 1977; 40: 2209-15.
225. Hiroshima K, Toyozaki T, Iyoda A, et al. Ultrastructural study of intranuclear inclusion bodies of pulmonary adenocarcinoma. Ultrastruct Pathol 1999; 23: 383-9.
226. Lu SH, Ohtsuki Y, Nonami Y, et al. Ultrastructural study of nuclear inclusions immunohistochemically positive for surfactant protein A in pulmonary adenocarcinoma with special reference to their morphogenesis. Med Mol Morphol 2006; 39: 214-20.
227. Tsumuraya M, Kodama T, Kameya T, et al. Light and electron microscopic analysis of intranuclear inclusions in papillary adenocarcinoma of the lung. Acta Cytol 1981; 25: 523-32.
228. Caruso RA. Intranuclear and intranucleolar tubular inclusions in gastric adenocarcinoma cells. Ultrastruct Pathol 1991; 15: 139-48.
229. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
230. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
231. Dacic S. EGFR assays in lung cancer. Adv Anat Pathol 2008; 15: 241-7.
232. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-11.
233. Toyooka S, Takano T, Kosaka T, et al. Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. Cancer Sci 2008; 99: 303-8.
234. Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 2008; 26: 5589-95.
235. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005; 23: 8081-92.
236. Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 2006; 12: 1647-53.
237. D’Angelo SP, Park B, Azzoli CG, et al. Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center. J Thorac Cardiovasc Surg 2011; 141: 476-80.
238. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-smallcell lung cancer. J Clin Oncol 2005; 23: 5892-9.
239. Marks JL, Broderick S, Zhou Q, et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 2008; 3: 111-6.
240. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-46.
241. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008; 26: 1472-8.
242. Tamura K, Okamoto I, Kashii T, et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 2008; 98: 907-14.
243. Endo K, Sasaki H, Yano M, et al. Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy. Oncol Rep 2006; 16: 533-41.
244. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26: 2442-9.
245. Rosell R, Ichinose Y, Taron M, et al. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-smallcell lung cancer. Lung Cancer 2005; 50: 25-33.
246. Yang CH, Yu CJ, Shih JY, et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008; 26: 2745-53.
247. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.
248. Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005; 11: 5878-85.
249. Bamford S, Dawson E, Forbes S, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004; 91: 355-8.
250. Kaira K, Horie Y, Ayabe E, et al. Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis. J Thorac Oncol 2010; 5: 460-5.
251. Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006; 12: 5764-9.
252. Bos JL. The ras gene family and human carcinogenesis. Mutat Res 1988; 195: 255-71.
253. Mills NE, Fishman CL, Rom WN, Dubin N, Jacobson DR. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res 1995; 55: 1444-7.
254. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17.
255. Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008; 14: 5731-4.
256. Han SW, Kim TY, Jeon YK, et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 2006; 12: 2538-44.
257. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23: 5900-9.
258. Finberg KE, Sequist LV, Joshi VA, et al. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 2007; 9: 320-6.
259. Hata A, Katakami N, Fujita S, et al. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma. J Thorac Oncol 2010; 5: 1197-200.
260. Graziano SL, Gamble GP, Newman NB, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol 1999; 17: 668-75.
261. Pelosi G, Scarpa A, Manzotti M, et al. K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung. Mod Pathol 2004; 17: 538-46.
262. Italiano A, Cortot AB, Ilie M, et al. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. Int J Cancer 2009; 125: 2479-82.
263. Przygodzki RM, Koss MN, Moran CA, et al. Pleomorphic (giant and spindle cell) carcinoma is genetically distinct from adenocarcinoma and squamous cell carcinoma by K-ras-2 and p53 analysis. Am J Clin Pathol 1996; 106: 487-92.
264. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65.
265. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-smallcell lung cancer. Nature 2007; 448: 561-6.
266. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363: 1734-9.
267. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008; 3: 13-7.
268. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009; 115: 1723-33.
269. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009; 15: 5216-23.
270. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
271. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011; 29: 2046-51.
272. Yousem SA, Nikiforova M, Nikiforov Y. The histopathology of BRAF-V600E-mutated lung adenocarcinoma. Am J Surg Pathol 2008; 32: 1317-21.
273. Whittaker S, Menard D, Kirk R, et al. A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF. Cancer Res 2010; 70: 8036-44.
274. Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998; 391: 184-7.
275. Okudela K, Suzuki M, Kageyama S, et al. PIK3CA mutation and amplification in human lung cancer. Pathol Int 2007; 57: 664-71.
276. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
277. Ludovini V, Bianconi F, Pistola L, et al. Phosphoinositide-3-Kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011; 6: 707-15.
278. van Eijk R, Licht J, Schrumpf M, et al. Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS One 2011; 6: e17791.
279. Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res 2008; 68: 5524-8.
280. Kwei KA, Kim YH, Girard L, et al. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 2008; 27: 3635-40.
281. Kendall J, Liu Q, Bakleh A, et al. Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci USA 2007; 104: 16663-8.
282. Barletta JA, Perner S, Iafrate AJ, et al. Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med 2009; 13: 1977-86.
283. Suda K, Murakami I, Katayama T, et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010; 16: 5489-98.
284. Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008; 68: 9479-87.
285. Goldstraw P. Lung. In Edge S, Byrd D, Compton C, eds. AJCC Cancer Staging Manual, 7th ed. New York: Springer-Verlag, 2010. pp. 252-70.
286. Maeda R, Yoshida J, Ishii G, et al. Poor prognostic factors in patients with stage IB non-small cell lung cancer according to the seventh edition TNM classification. Chest 2011; 139: 855-61.
287. Dacic S, Ionescu DN, Finkelstein S, Yousem SA. Patterns of allelic loss of synchronous adenocarcinomas of the lung. Am J Surg Pathol 2005; 29: 897-902.
288. Girard N, Deshpande C, Azzoli CG, et al. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. Chest 2010; 137: 46-52.
289. Girard N, Deshpande C, Lau C, et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol 2009; 33: 1752-64.
290. Girard N, Ostrovnaya I, Lau C, et al. Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clin Cancer Res 2009; 15: 5184-90.
291. Lau DH, Yang B, Hu R, Benfield JR. Clonal origin of multiple lung cancers: K-ras and p53 mutations determined by nonradioisotopic single-strand conformation polymorphism analysis. Diagn Mol Pathol 1997; 6: 179-84.
292. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg 1975; 70: 606-12.
293. Matsuzoe D, Hideshima T, Ohshima K, et al. Discrimination of double primary lung cancer from intrapulmonary metastasis by p53 gene mutation. Br J Cancer 1999; 79: 1549-52.
294. Nonami Y, Ohtuki Y, Sasaguri S. Study of the diagnostic difference between the clinical diagnostic criteria and results of immunohistochemical staining of multiple primary lung cancers. J Cardiovasc Surg (Torino)2003; 44: 661-5.
295. van Rens MT, Eijken EJ, Elbers JR, et al. p53 mutation analysis for definite diagnosis of multiple primary lung carcinoma. Cancer 2002; 94: 188-96.
296. Wang X, Christiani DC, Mark EJ, et al. Carcinogen exposure, p53 alteration, and K-ras mutation in synchronous multiple primary lung carcinoma. Cancer 1999; 85: 1734-9.
297. Wang X, Wang M, MacLennan GT, et al. Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst 2009; 101: 560-70.
298. Minami Y, Matsuno Y, Iijima T, et al. Prognostication of small-sized primary pulmonary adenocarcinomas by histopathological and karyometric analysis. Lung Cancer 2005; 48: 339-48.
299. Casey JJ, Stempel BG, Scanlon EF, Fry WA. The solitary pulmonary nodule in the patient with breast cancer. Surgery 1984; 96: 801-5.
300. Park SY, Kim BH, Kim JH, Lee S, Kang GH. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med 2007; 131: 1561-7.
301. Robens J, Goldstein L, Gown AM, Schnitt SJ. Thyroid transcription factor-1 expression in breast carcinomas. Am J Surg Pathol 2010; 34: 1881-5.
302. Gomez-Fernandez C, Mejias A, Walker G, Nadji M. Immunohistochemical expression of estrogen receptor in adenocarcinomas of the lung: the antibody factor. Appl Immunohistochem Mol Morphol 2010; 18: 137-41.
303. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2: 706-14.
304. Schrump DS, Giaccone G, Kelsy CR, et al. Non-small cell lung cancer. In DeVita VT, Lawrence TS, Rosenberg S, eds. Principles and Practice of Oncology, 7th ed. Philadelphia: Wolters Kluwer; Lippincott, Williams & Wilkins, 2008. pp. 887-95.
305. Janjigian YY, McDonnell K, Kris MG, et al. Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer 2010; 116: 670-5.
306. Sakurai H, Maeshima A, Watanabe S, et al. Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis. Am J Surg Pathol 2004; 28: 198-206.
307. Brechot JM, Chevret S, Charpentier MC, et al. Blood vessel and lymphatic vessel invasion in resected nonsmall cell lung carcinoma. Correlation with TNM stage and disease free and overall survival. Cancer 1996; 78: 2111-8.
308. Hiraoka K, Miyamoto M, Cho Y, et al. Concurrent infiltration by CD8þ T cells and CD4þ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006; 94: 275-80.
309. Roberts TE, Hasleton PS, Musgrove C, Swindell R, Lawson RA. Vascular invasion in non-small cell lung carcinoma. J Clin Pathol 1992; 45: 591-3.
310. Schuchert MJ, Schumacher L, Kilic A, et al. Impact of angiolymphatic and pleural invasion on surgical outcomes for stage I non-small cell lung cancer. Ann Thorac Surg 2011; 91: 1059-65.
311. Jokoji R, Yamasaki T, Minami S, et al. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALKpositive lung adenocarcinoma. J Clin Pathol 2010; 63: 1066-70.
312. Yoshida A, Tsuta K, Watanabe SI, et al. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer 2011; 72: 309-15.
313. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-smallcell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-91.
314. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Modern Pathol 2009; 22: 508-15.
315. Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009; 27: 1394-400.
316. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007; 25: 587-95.
317. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 4247-53.
318. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of nonsmall- cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2010; 17: 889-97.
319. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009; 15: 3143-9.
320. Cappuzzo F, Janne PA, Skokan M, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 2009; 20: 298-304.
321. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-43.
322. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009; 10: 281-9.
323. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
324. Tang Z, Du R, Jiang S, et al. Dual METEGFR combinatorial inhibition against T790M-EGFR-mediated erlotinibresistant lung cancer. Br J Cancer 2008; 99: 911-22.
325. Saito M, Schetter AJ, Mollerup S, et al. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res 2011; 17: 1875-82.
326. Cohen PR, Yoshizawa A, Motoi N, et al. Signet ring cell features (SRCF) in lung adenocarcinoma: a cytologic change rather than a histologic subtype? Mod Pathol 2010; 23: 404A.
327. Deshpande CG, Yoshizawa AK, Motoi N, et al. Clear cell change in lung adenocarcinoma: a cytologic change rather than a histologic variant. Mod Pathol 2009 22(66): 1595.
328. Barsky SH, Cameron R, Osann KE, Tomita D, Holmes EC. Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features. Cancer 1994; 73: 1163-70.
329. Furak J, Trojan I, Szoke T, et al. Bronchioloalveolar lung cancer: occurrence, surgical treatment and survival. Eur J Cardiothorac Surg 2003; 23: 818-23.
330. Kimula Y. A histochemical and ultrastructural study of adenocarcinoma of the lung. Am J Surg Pathol 1978; 2: 253-64.
331. Ebbert JO, Chhatwani L, Aubry MC, et al. Clinical features of bronchioloalveolar carcinoma with new histologic and staging definitions. J Thorac Oncol 2010; 5: 1213-20.
332. Hidaka N, Nagao K. Bronchioloalveolar carcinoma accompanied by severe bronchorrhea. Chest 1996; 110: 281-2.
333. Garfield DH, Cadranel JL, Wislez M, Franklin WA, Hirsch FR. The bronchioloalveolar carcinoma and peripheral adenocarcinoma spectrum of diseases. J Thorac Oncol 2006; 1: 344-59.
334. Akira M, Atagi S, Kawahara M, Iuchi K, Johkoh T. High-resolution CT findings of diffuse bronchioloalveolar carcinoma in 38 patients. AJR Am J Roentgenol 1999; 173: 1623-9.
335. Miyake H, Matsumoto A, Terada A, et al. Mucin-producing tumor of the lung: CT findings. J Thorac Imaging 1995; 10: 96-8.
336. Gaeta M, Vinci S, Minutoli F, et al. CT and MRI findings of mucin-containing tumors and pseudotumors of the thorax: pictorial review. Eur Radiol 2002; 12: 181-9.
337. Sica GL, Yoshizawa AL, Downey RJ, et al. Reassessment of the histologic spectrum of mucinous bronchioloalveolar carcinoma (mBAC). Mod Pathol 2008; 21: 351A.
338. Mazziotta RM, Borczuk AC, Powell CA, Mansukhani M. CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall. Appl Immunohistochem Mol Morphol 2005; 13: 55-60.
339. Saad RS, Cho P, Silverman JF, Liu Y. Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. Am J Clin Pathol 2004; 122: 421-7.
340. Weidner N. Pulmonary adenocarcinoma with intestinal-type differentiation. Ultrastruct Pathol 1992; 16: 7-10.
341. Casali C, Rossi G, Marchioni A, et al. A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice. J Thorac Oncol 2010; 5: 830-6.
342. Garfield DH, Cadranel J, West HL. Bronchioloalveolar carcinoma: the case for two diseases. Clin Lung Cancer 2008; 9: 24-9.
343. Maeshima A, Miyagi A, Hirai T, Nakajima T. Mucin-producing adenocarcinoma of the lung, with special reference to goblet cell type adenocarcinoma: immunohistochemical observation and Ki-ras gene mutation. Pathol Int 1997; 47: 454-60.
344. Maeshima A, Sakamoto M, Hirohashi S. Mixed mucinous-type and non-mucinous-type adenocarcinoma of the lung: immunohistochemical examination and K- ras gene mutation. Virchows Arch 2002; 440: 598-603.
345. Marchetti A, Buttitta F, Pellegrini S, et al. Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. J Pathol 1996; 179: 254-9.
346. Oka S, Hanagiri T, Uramoto H, et al. Surgical resection for patients with mucinous bronchioloalveolar carcinoma. Asian J Surg 2010; 33: 89-93.
347. Sakuma Y, Matsukuma S, Yoshihara M, et al. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. Am J Clin Pathol 2007; 128: 100-8.
348. Kakegawa S, Shimizu K, Sugano M, et al. Clinicopathological features of lung adenocarcinoma with KRAS mutations. Cancer 2011; 117: 4257-66.
349. Lau SK, Desrochers MJ, Luthringer DJ. Expression of thyroid transcription factor-1, cytokeratin 7, and cytokeratin 20 in bronchioloalveolar carcinomas: an immunohistochemical evaluation of 67 cases. Mod Pathol 2002; 15: 538-42.
350. Shah RN, Badve S, Papreddy K, et al. Expression of cytokeratin 20 in mucinous bronchioloalveolar carcinoma. Hum Pathol 2002; 33: 915-20.
351. Goldstein NS, Thomas M. Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies. Am J Clin Pathol 2001; 116: 319-25.
352. Nakajima T, Terashima T, Nishida J, Onoda M, Koide O. Treatment of bronchorrhea by corticosteroids in a case of bronchioloalveolar carcinoma producing CA19-9. Intern Med 2002; 41: 225-8.
353. Barlesi F, Doddoli C, Thomas P, et al. Bilateral bronchioloalveolar lung carcinoma: is there a place for palliative pneumonectomy? Eur J Cardiothorac Surg 2001; 20: 1113-6.
354. Homma S, Kawabata M, Kishi K, et al. Successful treatment of refractory bronchorrhea by inhaled indomethacin in two patients with bronchioloalveolar carcinoma. Chest 1999; 115: 1465-8.
355. Tamaoki J, Kohri K, Isono K, Nagai A. Inhaled indomethacin in bronchorrhea in bronchioloalveolar carcinoma: role of cyclooxygenase. Chest 2000; 117: 1213-4.
356. Jayaram G, Yaccob R, Liam CK. Mucinous carcinoma (colloid carcinoma) of the lung diagnosed by fine needle aspiration cytology: a case report. Malays J Pathol 2003; 25: 63-8.
357. Moran CA, Hochholzer L, Fishback N, Travis WD, Koss MN. Mucinous (socalled colloid) carcinomas of lung. Mod Pathol 1992; 5: 634-8.
358. Murai T, Hara M, Ozawa Y, et al. Mucinous colloid adenocarcinoma of the lung with lymph node metastasis showing numerous punctate calcifications. Clin Imaging 2011; 35: 151-5.
359. Maeda R, Isowa N, Onuma H, Miura H. Primary pulmonary mucinous (colloid) adenocarcinoma. Gen Thorac Cardiovasc Surg 2008; 56: 195-8.
360. Okimasa S, Kurimoto N. Mucinous (colloid) adenocarcinoma. Jpn J Thorac Cardiovasc Surg 2005; 53: 305-8.
361. Rossi G, Murer B, Cavazza A, et al. Primary mucinous (so-called colloid) carcinomas of the lung: a clinicopathologic and immunohistochemical study with special reference to CDX-2 homeobox gene and MUC2 expression. Am J Surg Pathol 2004; 28: 442-52.
362. Brownlee NA, Mott RT, Mahar A, Roggli VL. Mucinous (colloid) adenocarcinoma of the lung. Arch Pathol Lab Med 2005; 129: 121-2.
363. Yousem SA. Pulmonary intestinal-type adenocarcinoma does not show enteric differentiation by immunohistochemical study. Mod Pathol 2005; 18: 816-21.
364. Gao ZH, Urbanski SJ. The spectrum of pulmonary mucinous cystic neoplasia: a clinicopathologic and immunohistochemical study of ten cases and review of literature. Am J Clin Pathol 2005; 124: 62-70.
365. Ishibashi H, Moriya T, Matsuda Y, et al. Pulmonary mucinous cystadenocarcinoma: report of a case and review of the literature. Ann Thorac Surg 2003; 76: 1738-40.
366. Roux FJ, Lantuejoul S, Brambilla E, Brambilla C. Mucinous cystadenoma of the lung. Cancer 1995; 76: 1540-4.
367. Traub B. Mucinous cystadenoma of the lung. Arch Pathol Lab Med 1991; 115: 740-1.
368. Guimaraes ch, Wain JC, Mark EJ, Wittram C. Mucinous cystadenoma of the lung. AJR Am J Roentgenol 2004; 183: 282.
369. Dixon AY, Moran JF, Wesselius LJ, McGregor DH. Pulmonary mucinous cystic tumor. Case report with review of the literature. Am J Surg Pathol 1993; 17: 722-8.
370. Davison AM, Lowe JW, Da Costa P. Adenocarcinoma arising in a mucinous cystadenoma of the lung. Thorax 1992; 47: 129-30.
371. Graeme-Cook F, Mark EJ. Pulmonary mucinous cystic tumors of borderline malignancy. Hum Pathol 1991; 22: 185-90.
372. Mann GN, Wilczynski SP, Sager K, Grannis FW Jr. Recurrence of pulmonary mucinous cystic tumor of borderline malignancy. Ann Thorac Surg 2001; 71: 696-7.
373. Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R. Cystic mucinous adenocarcinoma of the lung. Two cases of cystic variant of mucusproducing lung adenocarcinoma. Chest 1992; 101: 763-6.
374. Kragel PJ, Devaney KO, Meth BM, et al. Mucinous cystadenoma of the lung. A report of two cases with immunohistochemical and ultrastructural analysis. Arch Pathol Lab Med 1990; 114: 1053-6.
375. Matsuo T, Yusuke Kimura N, Takamori S, Shirouzu K. Recurrent pulmonary mucinous cystadenoma. Eur J Cardiothorac Surg 2005; 28: 176-7.
376. Kradin RL, Young RH, Dickersin GR, Kirkham SE, Mark EJ. Pulmonary blastoma with argyrophil cells and lacking sarcomatous features (pulmonary endodermal tumor resembling fetal lung). Am J Surg Pathol 1982; 6: 165-72.
377. Kodama T, Shimosato Y, Watanabe S, et al. Six cases of well-differentiated adenocarcinoma simulating fetal lung tubules in pseudoglandular stage. Comparison with pulmonary blastoma. Am J Surg Pathol 1984; 8: 735-44.
378. Nakatani Y, Kitamura H, Inayama Y, et al. Pulmonary adenocarcinomas of the fetal lung type: a clinicopathologic study indicating differences in histology, epidemiology, and natural history of low-grade and high-grade forms. Am J Surg Pathol 1998; 22: 399-411.
379. Siegel RJ, Bueso-Ramos C, Cohen C, Koss M. Pulmonary blastoma with germ cell (yolk sac) differentiation: report of two cases. Mod Pathol 1991; 4: 566-70.
380. Wong RP, Hwang WS, Field SK. Familial adenomatous polyposis and lung cancer. J Surg Oncol 1995; 60: 213-4.
381. Nakatani Y, Masudo K, Miyagi Y, et al. Aberrant nuclear localization and gene mutation of beta-catenin in low-grade adenocarcinoma of fetal lung type: upregulation of the Wnt signaling pathway may be a common denominator for the development of tumors that form morules. Mod Pathol 2002; 15: 617-24.
382. Koss MN, Hochholzer L, O’Leary T. Pulmonary blastomas. Cancer 1991; 67: 2368-81.
383. Nakatani Y, Dickersin GR, Mark EJ. Pulmonary endodermal tumor resembling fetal lung: a clinicopathologic study of five cases with immunohistochemical and ultrastructural characterization. Hum Pathol 1990; 21: 1097-107.
384. DiFurio MJ, Auerbach A, Kaplan KJ. Well-differentiated fetal adenocarcinoma: rare tumor in the pediatric population. Pediatr Dev Pathol 2003; 6: 564-7.
385. Singh SP, Besner GE, Schauer GM. Pulmonary endodermal tumor resembling fetal lung: report of a case in a 14-year-old girl. Pediatr Pathol Lab Med 1997; 17: 951-8.
386. Longo M, Levra MG, Capelletto E, et al. Fetal adenocarcinoma of the lung in a 25-year-old woman. J Thorac Oncol 2008; 3: 441-3.
387. Paull DE, Moezzi J, Katz N, Little AG, Adebonojo SA. Positron emission tomography in well differentiated fetal adenocarcinoma of the lung. Clin Nucl Med 2006; 31: 213-4.
388. Sheehan KM, Curran J, Kay EW, Broe P, Grace A. Well differentiated fetal adenocarcinoma of the lung in a 29 year old woman. J Clin Pathol 2003; 56: 478-9.
389. Ito T, Noguchi Y, Udaka N, Kitamura H, Satoh S. Glucose transporter expression in developing fetal lungs and lung neoplasms. Histol Histopathol 1999; 14: 895-904.
390. Babycos PB, Daroca PJ Jr. Polypoid pulmonary endodermal tumor resembling fetal lung: report of a case. Mod Pathol 1995; 8: 303-6.
391. Mardini G, Pai U, Chavez AM, Tomashefski JF Jr. Endobronchial adenocarcinoma with endometrioid features and prominent neuroendocrine differentiation. A variant of fetal adenocarcinoma. Cancer 1994; 73: 1383-9.
392. Gamachi A, Kashima K, Daa T, et al. Aberrant intranuclear localization of biotin, biotin-binding enzymes, and beta-catenin in pregnancy-related endometrium and morule-associated neoplastic lesions. Mod Pathol 2003; 16: 1124-31.
393. Nakatani Y, Kitamura H, Inayama Y, Ogawa N. Pulmonary endodermal tumor resembling fetal lung. The optically clear nucleus is rich in biotin. Am J Surg Pathol 1994; 18: 637-42.
394. Nakatani Y, Masudo K, Nozawa A, et al. Biotin-rich, optically clear nuclei express estrogen receptor-beta: tumors with morules may develop under the influence of estrogen and aberrant betacatenin expression. Hum Pathol 2004; 35: 869-74.
395. Geisinger KR, Travis WD, Perkins LA, Zakowski MF. Aspiration cytomorphology of fetal adenocarcinoma of the lung. Am J Clin Pathol 2010; 134: 894-902.
396. Kneafsey P, Duggan MA, McFadden S. Fine needle aspiration cytology of pulmonary, well-differentiated fetal adenocarcinoma prepared by the ThinPrep method. Cytopathology 2003; 14: 87-90.
397. Proctor L, Folpe AL, Esper A, et al. Well-differentiated fetal adenocarcinoma of the lung: cytomorphologic features on fineneedle aspiration with emphasis on use of beta-catenin as a useful diagnostic marker. Diagn Cytopathol 2007; 35: 39-42.
398. Garcia-Escudero A, Gonzalez-Campora R, Villar-Rodriguez JL, Lag-Asturiano E. Thyroid transcription factor-1 expression in pulmonary blastoma. Histopathology 2004; 44: 507-8.
399. Mulamalla K, Truskinovsky AM, Dudek AZ. Pulmonary blastoma with renal metastasis responds to sorafenib. J Thorac Oncol 2007; 2: 344-7.
400. Yamazaki K. Pulmonary welldifferentiated fetal adenocarcinoma expressing lineage-specific transcription factors (TTF-1 and GATA-6) to respiratory epithelial differentiation: an immunohistochemical and ultrastructural study. Virchows Arch 2003; 442: 393-9.
401. Wani Y, Notohara K, Nakatani Y, Matsuzaki A. Aberrant nuclear Cdx2 expression in morule-forming tumours in different organs, accompanied by cytoplasmic reactivity. Histopathology 2009; 55: 465-8.
402. Sekine S, Shibata T, Matsuno Y, et al. Beta-catenin mutations in pulmonary blastomas: association with morule formation. J Pathol 2003; 200: 214-21.
403. Shiojima K, Hayakawa K, Mitsuhashi N, Nakajima T, Niibe H. An autopsy case of pulmonary adenocarcinoma of fetal type treated with radiation therapy. Radiat Med 1994; 12: 36-8.
404. Hatanaka K, Tsuta K, Watanabe K, Sugino K, Uekusa T. Primary pulmonary adenocarcinoma with enteric differentiation resembling metastatic colorectal carcinoma: a report of the second case negative for cytokeratin 7. Pathol Res Pract 2011; 207: 188-91.
405. Inamura K, Satoh Y, Okumura S, et al. Pulmonary adenocarcinomas with enteric differentiation: histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas. Am J Surg Pathol 2005; 29: 660-5.
406. Li HC, Schmidt L, Greenson JK, Chang AC, Myers JL. Primary pulmonary adenocarcinoma with intestinal differentiation mimicking metastatic colorectal carcinoma: case report and review of literature. Am J Clin Pathol 2009; 131: 129-33.
407. Maeda R, Isowa N, Onuma H, Miura H. Pulmonary intestinal-type adenocarcinoma. Interact Cardiovasc Thorac Surg 2008; 7: 349-51.
408. Tsao MS, Fraser RS. Primary pulmonary adenocarcinoma with enteric differentiation. Cancer 1991; 68: 1754-7.
409. Colby TV, Koss MN, Travis WD. Carcinoma of the lung: clinical and radiographic aspects, spread, staging, management, and prognosis. In Colby TV, Koss MN, Travis WD, eds. Tumors of the Lower Respiratory Tract, 3rd ed. Washington DC: Armed Forces Institute of Pathology, 1995. pp. 107-34.